BridgeBio Pharma (FRA:2CL) Other Long Term Assets : €15.4 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Other Long Term Assets?

BridgeBio Pharma's other long-term assets for the quarter that ended in Mar. 2025 was €15.4 Mil.

BridgeBio Pharma's quarterly other long-term assets declined from Sep. 2024 (€18.3 Mil) to Dec. 2024 (€17.4 Mil) but then stayed the same from Dec. 2024 (€17.4 Mil) to Mar. 2025 (€15.4 Mil).

BridgeBio Pharma's annual other long-term assets increased from Dec. 2022 (€19.1 Mil) to Dec. 2023 (€20.7 Mil) but then declined from Dec. 2023 (€20.7 Mil) to Dec. 2024 (€17.4 Mil).

BridgeBio Pharma Other Long Term Assets Historical Data

The historical data trend for BridgeBio Pharma's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Other Long Term Assets Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long Term Assets

Get a 7-Day Free Trial

19.67

29.23

19.09

20.75

17.38

BridgeBio Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long Term Assets	Get a 7-Day Free Trial															19.06	17.56	18.28	17.38	15.36

BridgeBio Pharma Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

BBIO:USA

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Headlines

No Headlines